Psychiatry

Without FDA-approved medications or standardized detox protocols, clinicians face unique challenges treating methamphetamine addiction.

Stay updated with the latest healthcare breakthroughs, including notable FDA approvals and filings, in this week’s essential news roundup.

FDA expands lumateperone for relapse prevention in schizophrenia, White House boosts psychedelics research, and AI reshapes psychiatry care debates in April 2026.

Pickering discusses data linking social risk factors to hospitalization and costs in MDD and implications for screening and care models.

The FDA approved a lumateperone sNDA adding relapse prevention data in schizophrenia based on a 63% reduction in relapse risk versus placebo.

Alva discusses infrastructure gaps, training demands, and unmet psychiatric need amid accelerated policy momentum for psychedelic therapies.

Following an April 18 executive order, Gus Alva, MD, discusses psychedelic mechanisms, evidence, and clinical considerations for psychiatry.

Preventive cognitive therapy may reduce relapse in recurrent depression by strengthening positive affect and addressing anhedonia, van Tol explained.

Research suggests preventive cognitive therapy reduced relapse risk in recurrent depression by improving positive affect and anhedonia, van Tol explained in an interview.

Murrough discusses ADAA 2026 findings evaluating azetukalner in MDD with anhedonia; exploratory outcomes suggest potential benefit despite nonsignificant primary endpoints.

In this interview, Miller discusses patients using ChatGPT for mental health advice, risks in severe mental illness, and how clinicians respond.

King discusses real-world patient use of AI tools for mental health advice and implications for clinical conversations.

Wescott discusses ADAA 2026 findings linking sleeping less than usual to next-day depression in high-risk youth, with interpersonal reactivity emerging as a potential mechanism.

Engel discusses ADAA 2026 findings identifying fear of social judgment as a distinct component of food allergy–related anxiety in adolescents.

Sisti discusses ethics, safety, and guardrails as patients use ChatGPT for mental health support and clinicians navigate AI’s role in psychiatry.

Phase 2 data presented at ADAA 2026 suggest azetukalner may improve anhedonia in MDD, even though the trial did not meet its primary neuroimaging endpoint.

Yockey discusses why girls, older teens, and multiracial youth remain at greater risk for depression despite overall post-pandemic improvements.

FDA approvals, at-home neuromodulation, phase 3 psychedelic data, and rising AI therapy use impacted the psychiatry field in the first quarter of 2026.

Survey data show a nearly 40% drop in adolescent depressive episodes post-pandemic, though clinicians should remain vigilant for disparities and unmet care needs, Yockey says.

Interview with Xue on UK Biobank data linking first-onset depression after age 50 to cognitive deficits and increased dementia risk.

Rapid psychedelic therapies, accelerated TMS protocols, AI-driven care debates, and semaglutide’s link to reduced suicidality shaped psychiatry headlines in March 2026.

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

In part 3 of an interview, Michael E. Thase, MD, discusses retreatment timing, safety monitoring, and research priorities following phase 2b GH001 data.

An interview with Thase explores rapid antidepressant effects and real-world considerations for single-day individualized GH001 dosing in TRD.

Analysis of 75,064 UK Biobank participants found late-onset depression associated with worse fluid intelligence and visuospatial memory and a 42–52% increased dementia risk.